About C Test
C Test is a company based in Bengaluru (India). C Test offers products and services including C Test Kit and Oral Cancer Charity Services.
- Headquarter Bengaluru, India
- SectorsHealthcare
- Email••••••••
- Legal Name C Test Medicals Pvt. Ltd
- Date of Incorporation 22 May, 2012
- Jurisdiction Mumbai, Maharashtra, India
- Annual Revenue₹6.9 Lakh
FY 2023 · +49% YoY
- Net Loss-₹2.1 Lakh
FY 2023 · -30% margin
- EBITDA-₹1.9 Lakh
FY 2023 · -27% margin
Associated legal entities of C Test
C Test operates through C Test Medicals Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2023) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| C Test Medicals Private Limited CIN U73100MH2012PTC231323 | Active | 22 May 2012 | Mumbai, Maharashtra | ₹0.1 Cr | – | 4 | View details |
Products & Services of C Test
C Test offers a comprehensive portfolio of products and services, including C Test Kit and Oral Cancer Charity Services.
The kit is utilized for detecting oral cancer through non-invasive methods like brush biopsy and swivel biopsy.
These services are offered for providing free screening, treatment, and training to address oral cancer in underserved communities.
Board of directors of C Test Medicals Private Limited (C Test)
C Test Medicals Private Limited is the primary company behind C Test. The board of C Test Medicals Private Limited currently have 4 directors; the longest-serving is Mir Fahim Ali, appointed in 2017. 5 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Mir Fahim Ali DIN 07863998 | Director | 30 Jun 2017 | 9 yrs 3 mo | C Test Medicals Private Limited |
| Ali Hussaini Irani DIN 03028811 | Director | 01 Apr 2019 | 7 yrs 6 mo | C Test Medicals Private Limited |
| Ali Ettehad DIN 09432243 | Director | 15 Jan 2022 | 4 yrs 8 mo | C Test Medicals Private Limited |
| Zahra Sayed Hussein Hussaini DIN 01598744 | Additional Director | 25 Jun 2025 | 1 yr 3 mo | C Test Medicals Private Limited |
Financials of C Test
Figures of C Test Medicals Private Limited, the primary company behind C Test, for FY 2023. Revenue was ₹6.9 Lakh (+49% year on year). Net loss was -₹2.1 Lakh (-30% margin). EBITDA was -₹1.9 Lakh (-27% margin). Revenue has grown at a compounded annual rate of +88% over three years and +160% over five years.
- ₹6.9 LakhRevenue · FY 2023 · +49% YoY
- -₹2.1 LakhNet loss · -30% margin
- -₹1.9 LakhEBITDA · -27% margin
- ₹9 LakhPaid-up capital
- +88%Revenue CAGR, 3 years
- +160%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of C Test Medicals Private Limited are on its company page.
Detailed financial statements for C Test
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to C Test
10 companies that operate in the same segment as C Test (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about C Test
C Test is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
The primary company behind C Test, C Test Medicals Private Limited, reported revenue of ₹6.9 Lakh for FY 2023, up 49% year on year.
C Test is identified as a pioneering diagnostic tool that has been developed for the early identification of oral cancer, allowing detection at precancerous stages through painless, non-invasive procedures. It is noted that the test involves tissue sample analysis in digitalized laboratories, supported by computer-aided pathology, which aids in reducing global oral cancer mortality rates. The initiative includes charity efforts for free screenings and treatments in rural areas, while kits are made available for purchase. Invented by Dr. Zahra Hussaini, it addresses a major health issue in India, where oral cancer constitutes a significant portion of cases, emphasizing awareness and prevention strategies to improve survival rates.
C Test offers C Test Kit and Oral Cancer Charity Services.
C Test operates through C Test Medicals Private Limited.
The legal entities of C Test currently have 4 directors, including Ali Ettehad, Mir Fahim Ali, Ali Hussaini Irani and others.